A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Study ID
- NCT07215390
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- APL-3007, pegcetacoplan (APL-2) — DRUGComplement C3 inhibitor
- APL-3007, pegcetacoplan (APL-2) — DRUGComplement C3 Inhibitor
- Placebo, Syfovre — OTHERComplement C3 Inhibitor
Study Details
A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Key Dates
- Start date
- Jun 23, 2025
- Status verified
- Oct 2025
- Primary completion
- Jun 30, 2027
- Completion
- Nov 30, 2027
Study Design
- Enrollment
- 240 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Group 1 (APL-3007 Dose/Frequency 1 )APL-3007 SC + pegcetacoplan (APL-2)
- Experimental: Group 2 (APL-3007 Dose/Frequency 2)APL-3007 + pegcetacoplan (APL-2)
- Placebo Comparator: Group 3 (placebo)Placebo SC + pegcetacoplan (APL-2)
Primary Outcome Measure
Change from baseline (CFB) in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion in the study eye [ Time Frame: At month 12 ]
Central Contacts
- Apellis Clinical Trial Information Line617-977-5700
Locations (68)
Find similar trials in Gilbert, AZ
By research site
Associated Retina Consultants (01065)· Gilbert, AZBarnet Dulaney Perkins Eye Center (01018)· Mesa, AZAssociated Retina Consultants - Phoenix· Phoenix, AZRetinal Research Institute, LLC (01021)· Phoenix, AZCalifornia Retina Consultants (CRC) - Bakersfield Office· Bakersfield, CAThe Retina Partners - Encino· Encino, CA
Related Studies
- Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular DegenerationRecruiting · i-Lumen Scientific AUS PTY LTD · Manchester, Connecticut
- Phase 2 Study of ADX-038 in Participants With Geographic AtrophyPHASE2 · Recruiting · ADARx Pharmaceuticals, Inc. · Gilbert, Arizona
- A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)Recruiting · Complement Therapeutics · Mountain View, California
- An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)PHASE1/PHASE2 · Recruiting · Complement Therapeutics · Carmel, Indiana